Aadi Bioscience reports FY2023 revenue $24.4M (+60% YoY); net loss $65.8M

Whitehawk Therapeutics, Inc.

FYARRO net sales $24.4M for FY2023, up 60% YoY; Q4 sales $6.3M (+21% YoY).
Net loss $65.8M for FY2023 vs $60.5M in 2022; cash $108.8M funding into Q4 2025.
PRECISION1 trial enrollment on track to complete by May 2024; two-thirds interim analysis expected Q3 2024.
Phase 2 trials in accelerated endometrial cancer (EEC) and neuroendocrine tumors (NETs) actively enrolling.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Whitehawk Therapeutics, Inc. reported Full year ended December 31, 2023 results: revenue $24.4 million, net income -$65.8 million.

Period: Full year ended December 31, 2023
Revenue: $24.4 million
Net income: -$65.8 million
Result: reported results

Exact text from the filing

(EX-99.1) --- Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update FYARRO® sales of $6.3 million for Q4 2023 and $24.4 million for FY 2023 representing year-over-year growth of 21% and 60%, respectively Registration-directed PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Whitehawk Therapeutics, Inc. reported Three months ended December 31, 2023 results: revenue $6.3 million, net income -$16.3 million.

Period: Three months ended December 31, 2023
Revenue: $6.3 million
Net income: -$16.3 million
Result: reported results

Exact text from the filing

Total revenue for the quarter ended December 31, 2023, was $6.3 million, and $24.4 million for the full-year ended December 31, 2023, resulting from sales of FYARRO.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-010791

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.